http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Jul 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html si-local-file:///var/storage/secattach/20260729/26835278.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html Wed, 29 Jul 2026 16:16:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html si-local-file:///var/storage/secattach/20260729/26835278.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html Wed, 29 Jul 2026 16:16:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html si-local-file:///var/storage/secattach/20260729/26835278.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Citibank%2CN.A.ADR/26835278.html Wed, 29 Jul 2026 16:16:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html si-local-file:///var/storage/secattach/20260729/26834752.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html Wed, 29 Jul 2026 16:02:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html si-local-file:///var/storage/secattach/20260729/26834752.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html Wed, 29 Jul 2026 16:02:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html si-local-file:///var/storage/secattach/20260729/26834752.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+30/26834752.html Wed, 29 Jul 2026 16:02:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/Investing/Teva+seeks+clarity+on+Trump+drug+tariff+plans%2C+CEO+says/26832279.html <p>Investing.com -- Teva Pharmaceutical Industries said today it is seeking guidance from the U.S. government regarding the Trump administration's plan to impose tariffs on generic drugs imported into the United States over the next two years.</p><p>CEO Richard Francis said the company needs to understand what the administration aims to achieve with the tariff policy. He spoke after the Israeli drugmaker released its second-quarter financial results.</p><p>"We have a good seat at the table" as a "major player in the U.S. healthcare ecosystem," Francis told Reuters.</p><p>Francis said Teva is in talks with the U.S. government on the most favored nation issue and http://www.streetinsider.com/Investing/Teva+seeks+clarity+on+Trump+drug+tariff+plans%2C+CEO+says/26832279.html Wed, 29 Jul 2026 10:21:16 -0400 TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA